Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results.
Viatris said it will acquire Pacira BioSciences for $1.65 billion in cash, or $36.50 a share, a roughly 45% premium to Pacira's Wednesday close. The deal is expected to close by year-end and was followed by a 44% jump in Pacira shares and a 2.2% decline in Viatris.
Viatris Inc. (NASDAQ: VTRS ) announced Thursday that it agreed to acquire Pacira BioSciences Inc. (NASDAQ: PCRX ) for $1.65 billion, strengthening its position in non-opioid pain management. Under the agreement, Viatris will pay $36.50 per share in cash for all outstanding Pacira shares. Viatris reported $886.5 million
Viatris said it will acquire Pacira BioSciences for $1.65 billion, or $36.50 a share, in cash. The company expects the deal to close by year-end and to have a minimal impact on gross leverage.
Viatris will pay $36.50 per share in cash for Pacira BioSciences, a roughly 45% premium to Pacira’s prior close, in a deal set to close by year-end.
Viatris said the referenced deal is anticipated to close by the end of 2026 and is expected to be immediately accretive to its financial guidance metrics.